- Clover Biopharmaceuticals Ltd's follow-up analysis for efficacy in the SPECTRA Phase 2/3 trial of SCB-2019 COVID-19 vaccine provided high and durable protection in individuals five months after the second dose.
- The follow-up analysis involved 26,400 individuals.
- Against any variant, efficacy was maintained at 100% against severe COVID-19 and 95% against COVID-19 associated hospitalizations at five months after the second dose in the primary vaccination setting.
- Additionally, there was no evidence that clinical efficacy declined over five months in individuals with prior infection who were subsequently boosted with SCB-2019.
- Clover's COVID-19 vaccine candidate combines Dynavax Technologies Corporation's (NASDAQ:DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
- A heterologous booster dose of SCB-2019 in individuals previously receiving two doses of AstraZeneca plc (NASDAQ:AZN) COVID-19 vaccine induced approximately 2-fold higher levels of neutralizing antibodies against the omicron variant compared to individuals receiving three doses of AstraZeneca's vaccine.
- A homologous booster dose of SCB-2019 in individuals with prior COVID-19 infection induced multi-fold higher levels of neutralizing antibodies against the omicron variant than individuals receiving three doses of AstraZeneca's COVID-19 vaccine.
- The submissions are anticipated to complete in mid-2022 for the China NMPA and by Q3 of 2022 for the WHO and EMA.
- Price Action: DVAX shares are up 3.10% at $11.31 during the premarket session on the last check Thursday.
